Gotham Asset Management LLC lessened its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 55.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 50,949 shares of the biopharmaceutical company's stock after selling 64,333 shares during the quarter. Gotham Asset Management LLC's holdings in TG Therapeutics were worth $1,534,000 as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. Arizona State Retirement System boosted its position in TG Therapeutics by 0.9% in the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock worth $1,283,000 after purchasing an additional 364 shares in the last quarter. Blue Trust Inc. grew its position in TG Therapeutics by 24.5% during the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 371 shares during the period. Summit Investment Advisors Inc. increased its holdings in TG Therapeutics by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock valued at $440,000 after buying an additional 463 shares in the last quarter. Brookstone Capital Management raised its position in shares of TG Therapeutics by 3.7% in the fourth quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company's stock worth $527,000 after acquiring an additional 624 shares during the period. Finally, Daymark Wealth Partners LLC boosted its stake in shares of TG Therapeutics by 1.7% during the 4th quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company's stock worth $1,249,000 after acquiring an additional 689 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company's stock.
Wall Street Analyst Weigh In
A number of equities analysts recently weighed in on the company. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and issued a $55.00 target price on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $40.80.
Check Out Our Latest Report on TG Therapeutics
TG Therapeutics Trading Up 1.4%
NASDAQ:TGTX traded up $0.49 during trading hours on Tuesday, hitting $35.47. The company had a trading volume of 1,492,004 shares, compared to its average volume of 2,991,568. TG Therapeutics, Inc. has a 1 year low of $15.16 and a 1 year high of $46.48. The company has a market cap of $5.63 billion, a P/E ratio of -354.66 and a beta of 2.21. The company has a 50-day moving average of $38.54 and a 200 day moving average of $34.08. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $120.86 million during the quarter, compared to analysts' expectations of $117.07 million. During the same quarter in the prior year, the firm earned ($0.07) EPS. TG Therapeutics's revenue for the quarter was up 90.4% compared to the same quarter last year. Sell-side analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.
TG Therapeutics Company Profile
(
Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Featured Articles
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
